Targeting Toll-like receptors: emerging therapeutics? (original) (raw)

• O'Neill, L. Targeting signal transduction as a strategy to treat inflammatory diseases. Nature Rev. Drug Discov. 5, 549–563 (2006).
  CAS Google Scholar
• Koropatnick, T. A. et al. Microbial factor-mediated development in a host–bacterial mutualism. Science 306, 1186–1188 (2004).
  CAS PubMed Google Scholar
• Park, B. S. et al. The structural basis of lipopolysaccharide recognition by the TLR4–MD-2 complex. Nature 458, 1191–1195 (2009). References 3, 6 and 7 are the first studies to illustrate the crystal structures for TLR4, TLR3 and the TLR1–TLR2 heterodimer with their specific ligands.
  CAS PubMed Google Scholar
• Dziarski, R. & Gupta, D. Role of MD-2 in TLR2- and TLR4-mediated recognition of Gram-negative and Gram-positive bacteria and activation of chemokine genes. J. Endotoxin Res. 6, 401–405 (2000).
  CAS PubMed Google Scholar
• Carpenter, S. & O'Neill, L. A. Recent insights into the structure of Toll-like receptors and post-translational modifications of their associated signalling proteins. Biochem. J. 422, 1–10 (2009).
  CAS PubMed Google Scholar
• Liu, L. et al. Structural basis of toll-like receptor 3 signaling with double-stranded RNA. Science 320, 379–381 (2008).
  CAS PubMed PubMed Central Google Scholar
• Jin, M. S. et al. Crystal structure of the TLR1–TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 130, 1071–1082 (2007).
  CAS PubMed Google Scholar
• Kawai, T. & Akira, S. TLR signaling. Cell Death Differ. 13, 816–825 (2006).
  CAS PubMed Google Scholar
• Somani, N. & Rivers, J. K. Imiquimod 5% cream for the treatment of actinic keratoses. Skin Therapy Lett. 10, 1–6 (2005).
  CAS PubMed Google Scholar
• Stockfleth, E., Christophers, E., Benninghoff, B. & Sterry, W. Low incidence of new actinic keratoses after topical 5% imiquimod cream treatment: a long-term follow-up study. Arch. Dermatol. 140, 1542 (2004).
  PubMed Google Scholar
• Larange, A., Antonios, D., Pallardy, M. & Kerdine-Romer, S. TLR7 and TLR8 agonists trigger different signaling pathways for human dendritic cell maturation. J. Leukoc. Biol. 85, 673–683 (2009).
  CAS PubMed Google Scholar
• Lysa, B. et al. Gene expression in actinic keratoses: pharmacological modulation by imiquimod. Br. J. Dermatol. 151, 1150–1159 (2004).
  CAS PubMed Google Scholar
• Schwartz, D. & Cook, D. Polymorphisms of the Toll-like receptors and human disease. Clin. Infect. Dis. 41 (Suppl. 7), 403–407 (2005).
  Google Scholar
• Ishii, K. J. & Akira, S. Toll or toll-free adjuvant path toward the optimal vaccine development. J. Clin. Immunol. 27, 363–371 (2007).
  CAS PubMed Google Scholar
• Ehlers, M. & Ravetch, J. V. Opposing effects of Toll-like receptor stimulation induce autoimmunity or tolerance. Trends Immunol. 28, 74–79 (2007).
  CAS PubMed Google Scholar
• Meneghin, A. & Hogaboam, C. M. Infectious disease, the innate immune response, and fibrosis. J. Clin. Invest. 117, 530–538 (2007).
  CAS PubMed PubMed Central Google Scholar
• Rakoff-Nahoum, S. & Medzhitov, R. Toll-like receptors and cancer. Nature Rev. Cancer 9, 57–63 (2009).
  CAS Google Scholar
• Cho, Y. J., Ahn, B. Y., Lee, N. G., Lee, D. H. & Kim, D. S. A combination of E. coli DNA fragments and modified lipopolysaccharides as a cancer immunotherapy. Vaccine 24, 5862–5871 (2006).
  CAS PubMed Google Scholar
• Wei, M. Q., Mengesha, A., Good, D. & Anne, J. Bacterial targeted tumour therapy — dawn of a new era. Cancer Lett. 259, 16–27 (2008).
  CAS PubMed Google Scholar
• Hemmi, H. et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nature Immunol. 3, 196–200 (2002).
  CAS Google Scholar
• O'Neill, L. A., Bryant, C. E. & Doyle, S. L. Therapeutic targeting of toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol. Rev. 61, 177–197 (2009).
  CAS PubMed PubMed Central Google Scholar
• Lan, T. et al. Stabilized immune modulatory RNA compounds as agonists of Toll-like receptors 7 and 8. Proc. Natl Acad. Sci. USA 104, 13750–13755 (2007).
  CAS PubMed PubMed Central Google Scholar
• Dudek, A. Z. et al. First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer. Clin. Cancer Res. 13, 7119–7125 (2007).
  CAS PubMed Google Scholar
• Dummer, R. et al. An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma. Clin. Cancer Res. 14, 856–864 (2008).
  CAS PubMed Google Scholar
• Harrison, L. I., Astry, C., Kumar, S. & Yunis, C. Pharmacokinetics of 852A, an imidazoquinoline Toll-like receptor 7-specific agonist, following intravenous, subcutaneous, and oral administrations in humans. J. Clin. Pharmacol. 47, 962–969 (2007).
  CAS PubMed Google Scholar
• Agrawal, S. & Kandimalla, E. R. Synthetic agonists of Toll-like receptors 7, 8 and 9. Biochem. Soc. Trans. 35, 1461–1467 (2007).
  CAS PubMed Google Scholar
• Goodchild, A. et al. Primary leukocyte screens for innate immune agonists. J. Biomol. Screen 14, 723–730 (2009).
  CAS PubMed Google Scholar
• Krieg, A. M. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 27, 161–167 (2008).
  CAS PubMed Google Scholar
• Kochling, J. et al. Anti-tumor effect of DNA-based vaccination and dSLIM immunomodulatory molecules in mice with Ph+ acute lymphoblastic leukaemia. Vaccine 26, 4669–4675 (2008).
  PubMed Google Scholar
• Vollmer, J. et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur. J. Immunol. 34, 251–262 (2004).
  CAS PubMed Google Scholar
• Dorn, A. & Kippenberger, S. Clinical application of CpG-, non-CpG-, and antisense oligodeoxynucleotides as immunomodulators. Curr. Opin. Mol. Ther. 10, 10–20 (2008).
  CAS PubMed Google Scholar
• Schmidt, C. Clinical setbacks for toll-like receptor 9 agonists in cancer. Nature Biotech. 25, 825–826 (2007).
  CAS Google Scholar
• Salaun, B., Coste, I., Rissoan, M. C., Lebecque, S. J. & Renno, T. TLR3 can directly trigger apoptosis in human cancer cells. J. Immunol. 176, 4894–4901 (2006).
  CAS PubMed Google Scholar
• Panter G., K. A., Jerala R. Therapeutic applications of nucleic acids as ligands for Toll-like receptors. Curr. Opin. Mol. Ther. 11, 133–145 (2009).
  CAS PubMed Google Scholar
• D'Agostini, C. et al. Antitumour effect of OM-174 and cyclophosphamide on murine B16 melanoma in different experimental conditions. Int. Immunopharmacol. 5, 1205–1212 (2005).
  CAS PubMed Google Scholar
• Garay, R. P. et al. Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help. Eur. J. Pharmacol. 563, 1–17 (2007).
  CAS PubMed Google Scholar
• De Ridder, M. et al. The radiosensitizing effect of immunoadjuvant OM-174 requires cooperation between immune and tumor cells through interferon-γ and inducible nitric oxide synthase. Int. J. Radiat. Oncol. Biol. Phys. 66, 1473–1480 (2006).
  CAS PubMed Google Scholar
• Apetoh, L. et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nature Med. 13, 1050–1059 (2007).
  CAS PubMed Google Scholar
• Simons, M. P., O'Donnell, M. A. & Griffith, T. S. Role of neutrophils in BCG immunotherapy for bladder cancer. Urol. Oncol. 26, 341–345 (2008).
  CAS PubMed PubMed Central Google Scholar
• Murata, M. Activation of Toll-like receptor 2 by a novel preparation of cell wall skeleton from Mycobacterium bovis BCG Tokyo (SMP-105) sufficiently enhances immune responses against tumors. Cancer Sci. 99, 1435–1440 (2008).
  CAS PubMed Google Scholar
• Burdelya, L. G. et al. An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 320, 226–230 (2008).
  CAS PubMed PubMed Central Google Scholar
• Sfondrini, L. et al. Antitumor activity of the TLR-5 ligand flagellin in mouse models of cancer. J. Immunol. 176, 6624–6630 (2006).
  CAS PubMed Google Scholar
• Parkinson, T. The future of toll-like receptor therapeutics. Curr. Opin. Mol. Ther. 10, 21–31 (2008).
  CAS PubMed Google Scholar
• Schalm, S. W. et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J. Hepatol. 26, 961–966 (1997).
  CAS PubMed Google Scholar
• Mark, K. E. et al. Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial. J. Infect. Dis. 195, 1324–1331 (2007).
  CAS PubMed Google Scholar
• Pockros, P. J. et al. Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies. J. Hepatol. 47, 174–182 (2007).
  CAS PubMed Google Scholar
• Caron, G. et al. Direct stimulation of human T cells via TLR5 and TLR7/8: flagellin and R-848 up-regulate proliferation and IFN-γ production by memory CD4+ T cells. J. Immunol. 175, 1551–1557 (2005).
  CAS PubMed Google Scholar
• Kronenberger, B. & Zeuzem, S. Current and future treatment options for HCV. Ann. Hepatol. 8, 103–112 (2009).
  PubMed Google Scholar
• Barry, M. & Cooper, C. Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy. Expert Opin. Biol. Ther. 7, 1731–1737 (2007).
  CAS PubMed Google Scholar
• Harandi, A. M., Davies, G. & Olesen, O. F. Vaccine adjuvants: scientific challenges and strategic initiatives. Expert Rev. Vaccines 8, 293–298 (2009).
  CAS PubMed Google Scholar
• Gu, M., Hine, P. M., James Jackson, W., Giri, L. & Nabors, G. S. Increased potency of BioThrax anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CPG 10109. Vaccine 25, 526–534 (2007).
  CAS PubMed Google Scholar
• Krieg, A. M. Toll-free vaccines? Nature Biotech. 25, 303–305 (2007).
  CAS Google Scholar
• Mata-Haro, V. et al. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 316, 1628–1632 (2007). This study showed that the vaccine adjuvant MPLA has a bias towards TRIF-dependent signalling, which has important implications for the development of future therapies.
  CAS PubMed Google Scholar
• Gavin, A. L. et al. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 314, 1936–1938 (2006).
  CAS PubMed PubMed Central Google Scholar
• van Duin, D., Medzhitov, R. & Shaw, A. C. Triggering TLR signaling in vaccination. Trends Immunol. 27, 49–55 (2006).
  CAS PubMed Google Scholar
• Jasani, B., Navabi, H. & Adams, M. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer. Vaccine 27, 3401–3404 (2009).
  CAS PubMed Google Scholar
• Navabi, H. et al. A clinical grade poly I:C-analogue (Ampligen) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro. Vaccine 27, 107–115 (2009). A poly I:C analogue which stimulates dendritic cell maturation and IL-12 and induces much lower levels of IL-10 compared with poly I:C, has shown great promise as an adjuvant for cancer therapies.
  CAS PubMed Google Scholar
• Huleatt, J. W. et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 26, 201–214 (2008). This study showed that the use of a TLR-specific ligand coupled to an influenza protein can offer widespread protection against strains of influenza A.
  CAS PubMed Google Scholar
• Kanzler, H., Barrat, F. J., Hessel, E. M. & Coffman, R. L. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nature Med. 13, 552–559 (2007).
  CAS PubMed Google Scholar
• Gangloff, S. C. & Guenounou, M. Toll-like receptors and immune response in allergic disease. Clin. Rev. Allergy Immunol. 26, 115–125 (2004).
  CAS PubMed Google Scholar
• Kline, J. N. & Krieg, A. M. Toll-like receptor 9 activation with CpG oligodeoxynucleotides for asthma therapy. Drug News Perspect. 21, 434–439 (2008).
  CAS PubMed Google Scholar
• Heijink, I. H. & Van Oosterhout, A. J. Strategies for targeting T-cells in allergic diseases and asthma. Pharmacol. Ther. 112, 489–500 (2006).
  CAS PubMed Google Scholar
• Pastorelli, L., Pizarro, T. T., Cominelli, F. & Vecchi, M. Emerging drugs for the treatment of ulcerative colitis. Expert Opin. Emerg. Drugs 14, 505–521 (2009).
  CAS PubMed PubMed Central Google Scholar
• Baldrick, P., Richardson, D., Woroniecki, S. R. & Lees, B. Pollinex Quattro Ragweed: safety evaluation of a new allergy vaccine adjuvanted with monophosphoryl lipid A (MPL) for the treatment of ragweed pollen allergy. J. Appl. Toxicol. 27, 399–409 (2007).
  CAS PubMed Google Scholar
• DuBuske L. M., C. M.a.H. T. Significant reduction in combined symptom and medication score compared with placebo following MPL-adjuvanted uSCIT in patients with seasonal grass pollen allergy. J. of Allergy Clin. Immunol. 123, S216–S216 (2009).
  Google Scholar
• Feldmann, M. Translating molecular insights in autoimmunity into effective therapy. Annu. Rev. Immunol. 27, 1–27 (2009).
  CAS PubMed Google Scholar
• Klareskog, L. et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363, 675–681 (2004).
  CAS PubMed Google Scholar
• van der Heijde, D. et al. Inhibition of radiographic progression with combination etanercept and methotrexate in patients with moderately active rheumatoid arthritis previously treated with monotherapy. Ann. Rheum. Dis. 68, 1113–1118 (2009). This study demonstrates that the use of a combination therapy consisting of the antiTNF drug etanercept and methotrexate is much more efficacious in treating patients with moderate rheumatoid arthritis than either therapy alone.
  CAS PubMed Google Scholar
• Macfarlane, D. E. & Manzel, L. Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. J. Immunol. 160, 1122–1131 (1998).
  CAS PubMed Google Scholar
• Sun, S., Rao, N. L., Venable, J., Thurmond, R. & Karlsson, L. TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm. Allergy Drug Targets 6, 223–235 (2007).
  CAS PubMed Google Scholar
• Lipford G. et al. Selective Toll-like receptor 7/8/9 antagonists for the oral treatment of autoimmune diseases. American College of Rheumatology 2007 Annual Scientific Meeting (2007). ACR website [online], (2007).
  Google Scholar
• Barrat, F. J., Meeker, T., Chan, J. H., Guiducci, C. & Coffman, R. L. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur. J. Immunol. 37, 3582–3586 (2007). This study showed that in plasmacytoid dendritic cells isolated from patients with SLE, the TLR7 and TLR9 inhibitor IRS954 inhibited the production of IFNα in response to DNA and RNA from viruses. The compound prevented disease progression in SLE-prone mice.
  CAS PubMed Google Scholar
• Pawar, R. D. et al. Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. J. Am. Soc. Nephrol. 18, 1721–1731 (2007).
  CAS PubMed Google Scholar
• Jiang, W., Bhagat, L., Yu, D., Kandimalla, E. R. & Agrawal, S. IMO-3100, an antagonist of Toll-like receptors 7 and 9, modulates gene expression and regulatory networks induced by ligands. J. Immunol. 182, 48.25 (2009).
  Google Scholar
• Mullarkey, M. et al. Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J. Pharmacol. Exp. Ther. 304, 1093–1102 (2003).
  CAS PubMed Google Scholar
• Savov, J. D. et al. Toll-like receptor 4 antagonist (E5564) prevents the chronic airway response to inhaled lipopolysaccharide. Am. J. Physiol. Lung Cell. Mol. Physiol. 289, L329–L337 (2005).
  CAS PubMed Google Scholar
• Czeslick, E., Struppert, A., Simm, A. & Sablotzki, A. E5564 (Eritoran) inhibits lipopolysaccharide-induced cytokine production in human blood monocytes. Inflamm. Res. 55, 511–515 (2006).
  CAS PubMed Google Scholar
• Bennett-Guerrero, E. et al. A phase II, double-blind, placebo-controlled, ascending-dose study of Eritoran (E5564), a lipid A antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass. Anesth. Analg. 104, 378–383 (2007).
  CAS PubMed Google Scholar
• Wasan, K. M. et al. Influence of plasma cholesterol and triglyceride concentrations and eritoran (E5564) micelle size on its plasma pharmacokinetics and ex vivo activity following single intravenous bolus dose into healthy female rabbits. Pharm. Res. 25, 176–182 (2008).
  CAS PubMed Google Scholar
• Cluff, C. W. et al. Synthetic toll-like receptor 4 agonists stimulate innate resistance to infectious challenge. Infect. Immun. 73, 3044–3052 (2005).
  CAS PubMed PubMed Central Google Scholar
• Amlie-Lefond, C. et al. Innate immunity for biodefense: a strategy whose time has come. J. Allergy Clin. Immunol. 116, 1334–1342 (2005).
  CAS PubMed PubMed Central Google Scholar
• Ulevitch, R. J. Therapeutics targeting the innate immune system. Nature Rev. Immunol. 4, 512–520 (2004).
  CAS Google Scholar
• Ii, M. et al. A novel cyclohexene derivative, ethyl (6_R_)-6-[_N_-(2-Chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling. Mol. Pharmacol. 69, 1288–1295 (2006).
  CAS PubMed Google Scholar
• Ledeboer, A. et al. The glial modulatory drug AV411 attenuates mechanical allodynia in rat models of neuropathic pain. Neuron Glia Biol. 2, 279–291 (2006).
  PubMed Google Scholar
• Ledeboer, A., Hutchinson, M. R., Watkins, L. R. & Johnson, K. W. Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes. Expert Opin. Investig. Drugs 16, 935–950 (2007).
  CAS PubMed Google Scholar
• Ungaro, R. et al. A novel toll-like receptor 4 (TLR4) antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. Am. J. Physiol. Gastrointest Liver Physiol. 296, G1167–G1179 (2009).
  CAS PubMed PubMed Central Google Scholar
• Dunn-Siegrist, I. et al. Pivotal involvement of Fcγ receptor IIA in the neutralization of lipopolysaccharide signaling via a potent novel anti-TLR4 monoclonal antibody 15C1. J. Biol. Chem. 282, 34817–34827 (2007).
  CAS PubMed Google Scholar
• Chen, K. et al. Toll-like receptors in inflammation, infection and cancer. Int. Immunopharmacol. 7, 1271–1285 (2007).
  CAS PubMed Google Scholar
• Urbonaviciute, V. et al. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J. Exp. Med. 205, 3007–3018 (2008).
  CAS Google Scholar
• Arslan, F., de Kleijn, D. P., Timmers, L., Doevendans, P. A. & Pasterkamp, G. Bridging innate immunity and myocardial ischemia/reperfusion injury: the search for therapeutic targets. Curr. Pharm. Des 14, 1205–1216 (2008).
  CAS PubMed Google Scholar
• Chong, A. J. et al. Toll-like receptor 4 mediates ischemia/reperfusion injury of the heart. J. Thorac. Cardiovasc. Surg. 128, 170–179 (2004).
  CAS PubMed Google Scholar
• Hua, F. et al. Differential roles of TLR2 and TLR4 in acute focal cerebral ischemia/reperfusion injury in mice. Brain Res. 1262, 100–108 (2009).
  CAS PubMed PubMed Central Google Scholar
• Tang, S. C. et al. Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits. Proc. Natl Acad. Sci. USA 104, 13798–13803 (2007).
  CAS PubMed PubMed Central Google Scholar
• Chang, Y. C., Kao, W. C., Wang, W. Y., Yang, R. B. & Peck, K. Identification and characterization of oligonucleotides that inhibit Toll-like receptor 2-associated immune responses. FASEB J. 23, 3078–3088 (2009). This paper shows the development of a novel technique for identifying antagonistic TLR2 aptamers. Functional peptides were identified using a NF-κB reporter assay. One of the identified molecules reduced NF-κB by 80%.
  CAS PubMed Google Scholar
• Sheedy, F. J. & O'Neill, L. A. Adding fuel to fire: microRNAs as a new class of mediators of inflammation. Ann. Rheum. Dis. 67 (Suppl. 3), 50–55 (2008).
  Google Scholar
• Taganov, K. D., Boldin, M. P., Chang, K. J. & Baltimore, D. NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc. Natl Acad. Sci. USA 103, 12481–12486 (2006). This is the first study to show a miRNA can have a direct role on NF-κB signalling through the targeting of IRAK1 and TRAF6.
  CAS PubMed PubMed Central Google Scholar
• O'Connell, R. M., Chaudhuri, A. A., Rao, D. S. & Baltimore, D. Inositol phosphatase SHIP1 is a primary target of miR-155. Proc. Natl Acad. Sci. USA 106, 7113–7118 (2009).
  CAS PubMed PubMed Central Google Scholar
• Tili, E. et al. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-α stimulation and their possible roles in regulating the response to endotoxin shock. J. Immunol. 179, 5082–5089 (2007).
  CAS PubMed Google Scholar
• Harte, M. T. et al. The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense. J. Exp. Med. 197, 343–351 (2003).
  CAS PubMed PubMed Central Google Scholar
• McCoy, S. L., Kurtz, S. E., Macarthur, C. J., Trune, D. R. & Hefeneider, S. H. Identification of a peptide derived from vaccinia virus A52R protein that inhibits cytokine secretion in response to TLR-dependent signaling and reduces in vivo bacterial-induced inflammation. J. Immunol. 174, 3006–3014 (2005).
  CAS PubMed Google Scholar
• Tsung, A. et al. A novel inhibitory peptide of Toll-like receptor signaling limits lipopolysaccharide-induced production of inflammatory mediators and enhances survival in mice. Shock 27, 364–369 (2007).
  CAS PubMed Google Scholar
• Buckley, G. M. et al. IRAK-4 inhibitors. Part III: a series of imidazo[1,2-a]pyridines. Bioorg Med. Chem. Lett. 18, 3656–3660 (2008).
  CAS PubMed Google Scholar
• Cohen, P. Targeting protein kinases for the development of anti-inflammatory drugs. Curr. Opin. Cell Biol. 21, 317–324 (2009).
  CAS PubMed Google Scholar
• Koziczak-Holbro, M. et al. The critical role of kinase activity of interleukin-1 receptor-associated kinase 4 in animal models of joint inflammation. Arthritis Rheum. 60, 1661–1671 (2009).
  CAS PubMed Google Scholar
• Kawagoe, T. et al. Sequential control of Toll-like receptor-dependent responses by IRAK1 and IRAK2. Nature Immunol. 9, 684–691 (2008).
  CAS Google Scholar
• Nalepa, G., Rolfe, M. & Harper, J. W. Drug discovery in the ubiquitin-proteasome system. Nature Rev. Drug Discov. 5, 596–613 (2006).
  CAS Google Scholar
• Guedat, P. & Colland, F. Patented small molecule inhibitors in the ubiquitin proteasome system. BMC Biochem. 8 (Suppl. 1), S14 (2007).
  PubMed PubMed Central Google Scholar
• Cossu, F. et al. Structural basis for bivalent smac-mimetics recognition in the IAP protein family. J. Mol. Biol. 392, 630–644 (2009).
  CAS PubMed Google Scholar
• Cossu, F. et al. Designing Smac-mimetics as antagonists of XIAP, cIAP1, and cIAP2. Biochem. Biophys. Res. Commun. 378, 162–167 (2009).
  CAS PubMed Google Scholar
• Vince, J. E. et al. IAP antagonists target cIAP1 to induce TNFα-dependent apoptosis. Cell 131, 682–693 (2007). One of the first studies to show that IAP antagonists or SMAC mimetics could induce apoptosis of cancer cells by stimulating NF-κB and TNFα.
  CAS PubMed Google Scholar
• Vallabhapurapu, S. et al. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nature Immunol. 9, 1364–1370 (2008). This paper describes an alternative NF-κB activation pathway that involves an inhibitor of TLR signalling, TRAF2.
  CAS Google Scholar
• Latz, E. et al. Lipopolysaccharide rapidly traffics to and from the Golgi apparatus with the toll-like receptor 4-MD-2–CD14 complex in a process that is distinct from the initiation of signal transduction. J. Biol. Chem. 277, 47834–47843 (2002).
  CAS PubMed Google Scholar
• Hughes, A. L. & Piontkivska, H. Functional diversification of the toll-like receptor gene family. Immunogenetics 60, 249–256 (2008).
  CAS PubMed PubMed Central Google Scholar
• Underhill, D. et al. The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature 401, 811–815 (1999).
  CAS PubMed Google Scholar
• Medzhitov, R. & Janeway, C. J. The Toll receptor family and microbial recognition. Trends Microbiol. 8, 452–456 (2000).
  CAS PubMed Google Scholar
• Muzio, M. et al. Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J. Immunol. 164, 5998–6004 (2000).
  CAS PubMed Google Scholar
• Zarember, K. A. & Godowski, P. J. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J. Immunol. 168, 554–561 (2002).
  CAS PubMed Google Scholar
• Strandskog, G., Ellingsen, T. & Jorgensen, J. B. Characterization of three distinct CpG oligonucleotide classes which differ in ability to induce IFN α/β activity and cell proliferation in Atlantic salmon (Salmo salar L.) leukocytes. Dev. Comp. Immunol. 31, 39–51 (2007).
  PubMed Google Scholar
• Geddes, K., Magalhaes, J. G. & Girardin, S. E. Unleashing the therapeutic potential of NOD-like receptors. Nature Rev. Drug Discov. 8, 465–479 (2009).
  CAS Google Scholar
• Proell, M., Riedl, S. J., Fritz, J. H., Rojas, A. M. & Schwarzenbacher, R. The Nod-like receptor (NLR) family: a tale of similarities and differences. PLoS ONE 3, e2119 (2008).
  PubMed PubMed Central Google Scholar
• Fernandes-Alnemri, T., Yu, J. W., Datta, P., Wu, J. & Alnemri, E. S. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 458, 509–513 (2009).
  CAS PubMed PubMed Central Google Scholar
• Koizumi, K. et al. Single nucleotide polymorphisms in the gene encoding the major histocompatibility complex class II transactivator (CIITA) in systemic lupus erythematosus. Ann. Rheum. Dis. 64, 947–950 (2005).
  CAS PubMed PubMed Central Google Scholar
• Macaluso, F. et al. Polymorphisms in NACHT-LRR (NLR) genes in atopic dermatitis. Exp. Dermatol. 16, 692–698 (2007).
  CAS PubMed Google Scholar
• Magitta, N. F. et al. A coding polymorphism in NALP1 confers risk for autoimmune Addison's disease and type 1 diabetes. Genes Immun. 10, 120–124 (2009).
  CAS PubMed Google Scholar
• McGovern, D. P. et al. Association between a complex insertion/deletion polymorphism in NOD1 (CARD4) and susceptibility to inflammatory bowel disease. Hum. Mol. Genet. 14, 1245–1250 (2005).
  CAS PubMed Google Scholar
• Skinningsrud, B. et al. Polymorphisms in CLEC16A and CIITA at 16p13 are associated with primary adrenal insufficiency. J. Clin. Endocrinol. Metab. 93, 3310–3317 (2008).
  CAS PubMed Google Scholar
• Weidinger, S. et al. Association of NOD1 polymorphisms with atopic eczema and related phenotypes. J. Allergy Clin. Immunol. 116, 177–184 (2005).
  CAS PubMed Google Scholar
• Noguchi, E., Homma, Y., Kang, X., Netea, M. G. & Ma, X. A Crohn's disease-associated NOD2 mutation suppresses transcription of human IL10 by inhibiting activity of the nuclear ribonucleoprotein hnRNP-A1. Nature Immunol. 10, 471–479 (2009).
  CAS Google Scholar
• Ogura, Y. et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411, 603–606 (2001).
  CAS PubMed Google Scholar
• Maksimovic, L. et al. New CIAS1 mutation and anakinra efficacy in overlapping of Muckle-Wells and familial cold autoinflammatory syndromes. Rheumatology 47, 309–310 (2008).
  CAS PubMed Google Scholar
• Zapata, J. M. et al. Lymphocyte-specific TRAF3 transgenic mice have enhanced humoral responses and develop plasmacytosis, autoimmunity, inflammation, and cancer. Blood 113, 4595–4603 (2009).
  CAS PubMed PubMed Central Google Scholar
• Bochud, P. Y. et al. Toll-like receptor 2 (TLR2) polymorphisms are associated with reversal reaction in leprosy. J. Infect. Dis. 197, 253–261 (2008).
  CAS PubMed Google Scholar
• Thuong, N. T. et al. A polymorphism in human TLR2 is associated with increased susceptibility to tuberculous meningitis. Genes Immun. 8, 422–428 (2007).
  CAS PubMed Google Scholar
• Lorenz, E., Mira, J., Cornish, K., Arbour, N. & Schwartz, D. A novel polymorphism in the toll-like receptor 2 gene and its potential association with staphylococcal infection. Infect. Immun. 68, 6398–6401 (2000).
  CAS PubMed PubMed Central Google Scholar
• Agnese, D. et al. Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of Gram-negative infections. J. Infect. Dis. 186, 1522–1525 (2002).
  CAS PubMed Google Scholar
• Kiechl, S. et al. Toll-like receptor 4 polymorphisms and atherogenesis. N. Engl. J. Med. 347, 185–192 (2002).
  CAS PubMed Google Scholar
• Sheedy, F. J., Marinou, I., O'Neill, L. A. & Wilson, A. G. The Mal/TIRAP S180L and TLR4 G299D polymorphisms are not associated with susceptibility to, or severity of, rheumatoid arthritis. Ann. Rheum. Dis. 67, 1328–1331 (2008).
  CAS PubMed Google Scholar
• Gewirtz, A. T. et al. Dominant-negative TLR5 polymorphism reduces adaptive immune response to flagellin and negatively associates with Crohn's disease. Am. J. Physiol. Gastrointest Liver Physiol. 290, G1157–G1163 (2006).
  CAS PubMed Google Scholar
• Castiblanco, J. et al. TIRAP (MAL) S180L polymorphism is a common protective factor against developing tuberculosis and systemic lupus erythematosus. Infect. Genet. Evol. 8, 541–544 (2008).
  CAS PubMed Google Scholar
• Khor, C. C. et al. A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nature Genet. 39, 523–528 (2007).
  CAS PubMed Google Scholar
• Nejentsev, S. et al. Analysis of association of the TIRAP (MAL) S180L variant and tuberculosis in three populations. Nature Genet. 40, 261–262; author reply 262–263 (2008).
  CAS PubMed Google Scholar
• Ramasawmy, R. et al. Heterozygosity for the S180L variant of MAL/TIRAP, a gene expressing an adaptor protein in the toll-like receptor pathway, is associated with lower risk of developing chronic chagas cardiomyopathy. J. Infect. Dis. 199, 1838–1845 (2009).
  CAS PubMed Google Scholar
• Ferwerda, B. et al. Functional and genetic evidence that the Mal/TIRAP allele variant 180L has been selected by providing protection against septic shock. Proc. Natl Acad. Sci. USA 106, 10272–10277 (2009).
  CAS PubMed PubMed Central Google Scholar
• Demirci, F. Y. et al. Association of a common interferon regulatory factor 5 (IRF5) variant with increased risk of systemic lupus erythematosus (SLE). Ann. Hum. Genet. 71, 308–311 (2007).
  CAS PubMed Google Scholar
• Ferreiro-Neira, I. et al. Opposed independent effects and epistasis in the complex association of IRF5 to SLE. Genes Immun. 8, 429–438 (2007).
  CAS PubMed Google Scholar
• Tewfik, M. A. et al. Polymorphisms in interleukin-1 receptor-associated kinase 4 are associated with total serum IgE. Allergy 64, 746–753 (2009).
  CAS PubMed Google Scholar
• Day, N. et al. Interleukin receptor-associated kinase (IRAK-4) deficiency associated with bacterial infections and failure to sustain antibody responses. J. Pediatr. 144, 524–526 (2004).
  PubMed Google Scholar
• Picard, C. et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 299, 2076–2079 (2003).
  CAS PubMed Google Scholar
• Medvedev, A. E. et al. Distinct mutations in IRAK-4 confer hyporesponsiveness to lipopolysaccharide and interleukin-1 in a patient with recurrent bacterial infections. J. Exp. Med. 198, 521–531 (2003).
  CAS PubMed PubMed Central Google Scholar
• Picard, C. et al. Inherited human IRAK-4 deficiency: an update. Immunol. Res. 38, 347–352 (2007).
  CAS PubMed Google Scholar
• Dhiman, N. et al. Associations between SNPs in toll-like receptors and related intracellular signaling molecules and immune responses to measles vaccine: preliminary results. Vaccine 26, 1731–1736 (2008).
  CAS PubMed PubMed Central Google Scholar
• Sheedy, F. J. et al. Negative regulation of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nature Immunol. 11, 141–147 (2010).
  CAS Google Scholar